Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Suryakanta Acharya"'
Autor:
Kathrin Knochel, Patrick Stone, Nicola White, Sandra Martins Pereira, Jeff Hanna, Márcio Niemeyer-Guimarães, Mariam Safi, Julie Doherty, David Mockler, Suryakanta Acharya, Gary Mitchell, Pablo Hernández-Marrero, Adrienne McCann, Cordula Gebel, Miguel Vieira Martins
Publikováno v:
Palliative Medicine. 35:1-243
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::832604d610b246eaf9ede3d9b301de2a
https://doi.org/10.1177/02692163211035909
https://doi.org/10.1177/02692163211035909
Autor:
Suryakanta Acharya
Publikováno v:
Brachytherapy. 21:S94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6c7d1b73319e10bd631403a0b77e06c
https://doi.org/10.1016/j.brachy.2022.09.151
https://doi.org/10.1016/j.brachy.2022.09.151
Autor:
Suryakanta, Acharya
Publikováno v:
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. 27(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bca5cd95b5b1c53c346524963fd8db88
https://pubmed.ncbi.nlm.nih.gov/36299376
https://pubmed.ncbi.nlm.nih.gov/36299376
Autor:
Suryakanta Acharya
Publikováno v:
Journal of Geriatric Oncology. 12:S1-S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6defec8e62ff35397dcd8553f4046a63
https://doi.org/10.1016/s1879-4068(21)00329-5
https://doi.org/10.1016/s1879-4068(21)00329-5
Autor:
Suryakanta Acharya
Publikováno v:
Journal of Clinical Oncology. 40:1130-1130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f612d5c1992a2c271b3ac61755900e
https://doi.org/10.1200/jco.21.02291
https://doi.org/10.1200/jco.21.02291
Autor:
Suryakanta Acharya
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:PO-213
Background- Prostate cancer is the 2nd most common cancer in males, worldwide & not far behind lung cancer incidence. Radiation holds the potential to cure non-metastatic disease (T1b-T3a), however the old 8-week long conventional radiation treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27a3e5f2f6a72d5dcb99cb196fa34782
https://doi.org/10.1158/1538-7755.disp21-po-213
https://doi.org/10.1158/1538-7755.disp21-po-213
Autor:
Suryakanta Acharya
Publikováno v:
Molecular Cancer Therapeutics. 20:P083-P083
BACKGROUND Lung cancer is the most common cancer worldwide in males & a good number of patients present with metastatic disease. Though EGFR mutated patients respond to EGFR TKIs, resistance develops ultimately. Overcoming 3rd generation EGFR TKI res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb053580e944b9da7bb62f80c7fb5f1
https://doi.org/10.1158/1535-7163.targ-21-p083
https://doi.org/10.1158/1535-7163.targ-21-p083
Autor:
William Shaw, Suryakanta Acharya
Publikováno v:
South African Journal of Oncology, Vol 3, Iss 0, Pp e1-e38 (2019)
This conference report encompasses abstracts and posters presented at the First South African Congress of Oncology on ‘Transporting Cancer Care into 2020 and Beyond’, 08–11 August 2019, at Cape Town International Convention Centre, Cape Town, S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da946d26d48ad0501cefdb582aee0ba0
https://doi.org/10.4102/sajo.v3i0.90
https://doi.org/10.4102/sajo.v3i0.90